Hutchison China MediTech Limited Company Profile (LON:HCM)

About Hutchison China MediTech Limited

Hutchison China MediTech Limited logoHutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures markets and distributes prescription drugs and consumer health products in China.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: HCM
  • CUSIP:
Key Metrics:
  • Previous Close: $26.20
  • 50 Day Moving Average: $2193.99
  • 200 Day Moving Average: $2008.61
  • 52-Week Range: GBX 1,612.50 - GBX 2,470
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $1.27B
  • Outstanding Shares: 60,649,000
Additional Links:

Analyst Ratings

Consensus Ratings for Hutchison China MediTech Limited (LON:HCM) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: GBX 2,630

Analysts' Ratings History for Hutchison China MediTech Limited (LON:HCM)
Show:
DateFirmActionRatingPrice TargetDetails
2/20/2017Panmure GordonReiterated RatingBuyGBX 2,630View Rating Details
2/15/2017Beaufort SecuritiesReiterated RatingBuyView Rating Details
4/11/2016Stifel NicolausInitiated CoverageBuyView Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for Hutchison China MediTech Limited (LON:HCM)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Hutchison China MediTech Limited (LON:HCM)
Current Year EPS Consensus Estimate: $-0.58 EPS

Dividends

Dividend History for Hutchison China MediTech Limited (LON:HCM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Hutchison China MediTech Limited (LON:HCM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/21/2016Michael HowellInsiderSell3,000GBX 1,890£56,700
10/28/2016Michael HowellInsiderSell2,500GBX 1,860£46,500
10/26/2016Michael HowellInsiderSell3,000GBX 1,850£55,500
10/25/2016Michael HowellInsiderSell1,000GBX 1,840£18,400
10/24/2016Michael HowellInsiderSell339GBX 1,825£6,186.75
10/7/2016Michael HowellInsiderSell15,000GBX 1,790£268,500
8/4/2016Nash,ChristopherInsiderBuy42GBX 1,899£797.58
10/20/2015Nash,ChristopherInsiderBuy4,512GBX 2,195£99,038.40
4/21/2015Christopher NashInsiderBuy1,388GBX 1,800£24,984
4/15/2015Simon ToInsiderBuy28,000GBX 1,585£443,800
4/10/2015Simon ToInsiderBuy25,000GBX 1,421.50£355,375
4/7/2015Edith ShihInsiderBuy2,000GBX 1,385£27,700
4/2/2015Simon ToInsiderBuy10,000GBX 1,385£138,500
4/1/2015Edith ShihInsiderBuy15,000GBX 1,365£204,750
3/30/2015Edith ShihInsiderBuy13,000GBX 1,300£169,000
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Hutchison China MediTech Limited (LON:HCM)
DateHeadline
seekingalpha.com logoChi-Med Looks Outside Its Comfort Zone - Seeking Alpha (LON:HCM)
seekingalpha.com - February 22 at 5:47 PM
marketexclusive.com logoAnalyst Activity – Panmure Gordon Reiterates Buy on Hutchison China MediTech Limited (LON:HCM) - Market Exclusive (LON:HCM)
marketexclusive.com - February 20 at 5:07 PM
marketwired.com logoHutchison China Meditech Limited: Start of Phase II Savolitinib PSC trial in China - Marketwired (press release) (LON:HCM)
www.marketwired.com - February 20 at 10:50 AM
uk.finance.yahoo.com logoChi-Med Initiates a Phase II Study of Savolitinib in Pulmonary Sarcomatoid Carcinoma (LON:HCM)
uk.finance.yahoo.com - February 20 at 10:50 AM
marketwired.com logoHutchison China Meditech Limited: Savolitinib PRCC Results Presentation at ASCO GU - Marketwired (press release) (LON:HCM)
www.marketwired.com - February 16 at 5:33 PM
investors.com logoHutchison China MediTech Limited kicks off first human trial for potential new cancer drug - Proactive Investors USA & Canada (LON:HCM)
www.proactiveinvestors.com - February 16 at 5:33 PM
4-traders.com logoHutchison China MediTech : Chi-Med Initiates First-In-Human Clinical Trial of Novel FGFR Inhibitor HMPL-453 in Australia (LON:HCM)
www.4-traders.com - February 14 at 11:55 PM
finance.yahoo.com logoHutchison China Meditech Limited: Initiates Phase I of Novel FGFR Inhibitor HMPL-453 - Yahoo Finance (LON:HCM)
finance.yahoo.com - February 14 at 4:40 AM
proactiveinvestors.co.uk logoHutchison China MediTech Limited kicks off first human trial for potential new cancer drug - Proactive Investors UK (LON:HCM)
www.proactiveinvestors.co.uk - February 14 at 4:40 AM
iii.co.uk logoHUTCHISON CHINA MEDITECH (LON:HCM)
www.iii.co.uk - February 12 at 10:33 PM
streetinsider.com logoForm SC 13G Hutchison China MediTech Filed by: CK Hutchison Holdings Ltd (LON:HCM)
www.streetinsider.com - February 8 at 6:17 PM
News IconTechnical Trading Review on Shares of Hutchison China Meditech Ltd. (HCM.L) - Sherwood Daily (LON:HCM)
sherwooddaily.com - February 6 at 10:41 PM
finanznachrichten.de logoHUTCHISON CHINA MEDITECH LIMITED (LON:HCM)
www.finanznachrichten.de - February 1 at 4:23 AM
4-traders.com logoASCO GI 2017: Fruquintinib in Combination with Paclitaxel in 2L Gastric Cancer (LON:HCM)
www.4-traders.com - January 20 at 5:27 AM
finance.yahoo.com logoHutchison China Meditech Limited: Fruquintinib Phase I/II Clinical Data at ASCO GI - Yahoo Finance (LON:HCM)
finance.yahoo.com - January 17 at 3:38 PM
marketwired.com logoHutchison China Meditech Limited: Change of Directors - Marketwired (press release) (LON:HCM)
www.marketwired.com - January 17 at 3:38 PM
News IconChi-Med Initiates a Phase II Combination Study of Fruquintinib with Iressa (gefitinib) in First-Line Non-Small Cell Lung Cancer (LON:HCM)
www.cbs58.com - January 17 at 10:25 AM
4-traders.com logoHutchison China MediTech : Initiates Studies For Fruquintinib And Sulfatinib (LON:HCM)
www.4-traders.com - January 17 at 10:25 AM
marketwired.com logoHutchison China Meditech Limited: Sulfatinib Phase II Study in 2nd Line BTC in China (LON:HCM)
www.marketwired.com - January 17 at 10:25 AM
4-traders.com logoHutchison China MediTech : Change of Directors (LON:HCM)
www.4-traders.com - January 16 at 9:13 AM
marketwired.com logoHutchison China Meditech Limited: Fruquintinib Phase I/II Clinical Data at ASCO GI (LON:HCM)
www.marketwired.com - January 16 at 9:13 AM
News IconNewest Rating: Hutchison China Meditech Ltd (LON:HCM) Stock Buy Rating Reconfirmed at Panmure Gordon; The PT is GBX 2630.00 (LON:HCM)
www.whatsonthorold.com - January 10 at 6:33 PM
trustnet.com logoChi-Med Initiates HMPL-523 Clinical Trials (LON:HCM)
www.trustnet.com - January 10 at 4:24 AM
streetinsider.com logoHutchison China MediTech (HCM) Begins Phase 1 Of HMPL-523 Clinical Trials In China On Patients With Hematological Malignancies (LON:HCM)
www.streetinsider.com - January 10 at 4:24 AM
streetinsider.com logoHutchison China MediTech (HCM) Begins Phase 1 Of HMPL-523 Clinical Trials In China On Patients With ... - StreetInsider.com (LON:HCM)
www.streetinsider.com - January 10 at 4:24 AM
bloomberg.com logoChina’s Airpocalypse Paves a Path for New Cancer Medicines (LON:HCM)
www.bloomberg.com - January 5 at 6:36 PM
streetinsider.com logoForm 6-K Hutchison China MediTech For: Dec 31 - StreetInsider.com (LON:HCM)
www.streetinsider.com - December 30 at 6:02 PM
marketwired.com logoHutchison China Meditech Limited: Director's Share Dealing - Marketwired (press release) (LON:HCM)
www.marketwired.com - December 22 at 5:55 PM
investing.com logoHutchison China Meditech - WCLC: Positive Data Highlights Nsclc Pipeline - Investing.com (LON:HCM)
www.investing.com - December 11 at 5:04 PM
investing.com logoHutchison China Meditech - WCLC: Positive Data Highlights Nsclc Pipeline (LON:HCM)
www.investing.com - December 11 at 10:36 AM
marketwired.com logoHutchison China Meditech Limited: HMPL-523 Pre-clinical Data Presented at ASH - Marketwired (press release) (LON:HCM)
www.marketwired.com - December 6 at 10:59 PM
News IconChi-Med Presents Pre-clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 American Society of Hematology Annual Mee... (LON:HCM)
uk.advfn.com - December 6 at 10:38 AM
News IconHutchison China Meditech Limited: HMPL-523 Pre-clinical Data Presented at ASH (LON:HCM)
www.andhranews.net - December 6 at 10:38 AM
finance.yahoo.com logoChi-Med Presents Pre-clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 American Society of Hematology Annual Meeting (LON:HCM)
au.finance.yahoo.com - December 6 at 10:38 AM
News IconRating Summary: Panmure Gordon Analyst Reaffirmed GBX 2630.00 Price Target on ... (LON:HCM)
www.whatsonthorold.com - December 5 at 6:09 PM
marketwired.com logoHutchison China Meditech Limited: Total Voting Rights - Marketwired (press release) (LON:HCM)
www.marketwired.com - December 2 at 8:18 AM
marketwired.com logoHutchison China Meditech Limited: Exercise of Share Options - Marketwired (press release) (LON:HCM)
www.marketwired.com - November 30 at 10:47 PM
tmcnet.com logoChi-Med to Present Data from Proof-of-Concept Clinical Trials for Fruquintinib and Epitinib at the 17th World Conference on Lung Cancer ("WCLC") (LON:HCM)
technews.tmcnet.com - November 29 at 4:50 PM
tmcnet.com logoChi-Med to Present Data from Proof-of-Concept Clinical Trials for Fruquintinib and Epitinib at the 17th World Conference on Lung Cancer ("WCLC") (LON:HCM)
technews.tmcnet.com - November 29 at 4:50 PM
finance.yahoo.com logoChi-Med to Present Data from Proof-of-Concept Clinical Trials for Fruquintinib and Epitinib at the 17th World Conference on Lung Cancer (“WCLC”) (LON:HCM)
finance.yahoo.com - November 29 at 4:50 PM
finance.yahoo.com logoChi-Med to Present Data from Proof-of-Concept Clinical Trials for Fruquintinib and Epitinib at the 17th World Conference on Lung Cancer (“WCLC”) (LON:HCM)
finance.yahoo.com - November 29 at 4:50 PM
businesswire.com logoChi-Med Presents Phase I Clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 ACR/ARHP Annual Meeting - Business Wire (press release) (LON:HCM)
www.businesswire.com - November 14 at 9:28 AM
uk.finance.yahoo.com logoChi-Med Presents Phase I Clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 ACR/ARHP Annual Meeting (LON:HCM)
uk.finance.yahoo.com - November 14 at 9:28 AM
News IconChi-Med to Present at the Deutsche Bank ADR Virtual Investor Conference on Wednesday, November 16, 2016 - Yahoo Sports (LON:HCM)
sports.yahoo.com - November 11 at 10:39 PM
businesswire.com logoChi-Med Commercial Platform Joint Venture Receives US$59.5 Million Land Compensation Payment - Business Wire (press release) (LON:HCM)
www.businesswire.com - November 1 at 5:41 PM
directorstalkinterviews.com logoHutchison China MediTech Limited 38.2% Potential Upside Indicated by Panmure Gordon - DirectorsTalk Interviews (LON:HCM)
www.directorstalkinterviews.com - November 1 at 5:41 PM
proactiveinvestors.co.uk logoBeaufort Securities Breakfast Alert: Motif Bio, Hutchison China MediTech, Advanced Onotherapy and WPP (LON:HCM)
www.proactiveinvestors.co.uk - November 1 at 9:52 AM
ft.com logo[$$] Chi Med falls as non-exec sells down (LON:HCM)
www.ft.com - October 21 at 5:29 PM
capitalcube.com logoHutchison China MediTech Ltd. breached its 50 day moving average in a Bearish Manner : HCM-GB : October 18, 2016 (LON:HCM)
www.capitalcube.com - October 18 at 10:26 AM
seekingalpha.com logoBuy This Biotech For Its Deep Pipeline And China Exposure (LON:HCM)
seekingalpha.com - September 30 at 5:38 PM

Social

What is Hutchison China MediTech Limited's stock symbol?

Hutchison China MediTech Limited trades on the London Stock Exchange (LON) under the ticker symbol "HCM."

Where is Hutchison China MediTech Limited's stock going? Where will Hutchison China MediTech Limited's stock price be in 2017?

3 brokerages have issued 12 month price targets for Hutchison China MediTech Limited's stock. Their forecasts range from GBX 2,630 to GBX 2,630. On average, they expect Hutchison China MediTech Limited's share price to reach GBX 2,630 in the next twelve months.

When will Hutchison China MediTech Limited announce their earnings?

Hutchison China MediTech Limited is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.

How do I buy Hutchison China MediTech Limited stock?

Shares of Hutchison China MediTech Limited and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

How much does a share of Hutchison China MediTech Limited stock cost?

One share of Hutchison China MediTech Limited stock can currently be purchased for approximately GBX 2,102.50.


Last Updated on 2/24/2017 by MarketBeat.com Staff